Physician profile
Michael Sension
NPI 1790749661
$1,010,027.66
in general payments reported to CMS, 2019-2025
18 companies · $161K in 2025
The $161K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204K · 2020: $56K · 2021: $83K · 2022: $98K · 2023: $196K · 2024: $212K · 2025: $161K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $450K · Travel and Lodging: $77K · Food and Beverage: $25K · Consulting Fee: $16K · Education: $83.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $450,113.50 |
| Travel and Lodging | $76,569.75 |
| Food and Beverage | $25,403.23 |
| Consulting Fee | $16,290.00 |
| Education | $83.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $503,146.36 | 2019-2025 | Rukobia, Dovato, Cabenuva |
| Gilead Sciences, INC. | $442,718.75 | 2019-2025 | Biktarvy, Descovy, Yeztugo |
| Janssen Scientific Affairs, LLC | $28,952.64 | 2019-2023 | Symtuza |
| Janssen Products, Lp | $19,962.73 | 2019 | |
| Merck Sharp & Dohme LLC | $11,715.20 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Glaxosmithkline, LLC. | $1,192.65 | 2019-2023 | Shingrix, Arexvy |
| Emd Serono, INC. | $663.52 | 2019-2025 | Serostim |
| Theratechnologies INC. | $372.64 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $367.78 | 2019-2023 | Symtuza |
| Abbvie INC. | $327.19 | 2019-2025 | |
| Napo Pharmaceuticals INC | $146.79 | 2022-2025 | Mytesi |
| Allergan, INC. | $127.90 | 2019 | |
| Mylan Specialty L.P. | $124.99 | 2021 | |
| Myocardial Solutions, INC. | $89.35 | 2021 | |
| Pfizer INC. | $53.18 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.15 | 2025 | Repatha, Otezla |
| Vyera Pharmaceuticals, LLC | $20.17 | 2020 | |
| Halozyme INC | $17.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sension listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.